< Back to companies
Somite AI

Somite AI

Boston, Massachusetts, United States

Somite.ai is a venture-backed company aiming to become the OpenAI of stem cell biology, developing AI foundation models to produce human tissue for cell therapies at scale for diseases such as diabetes, obesity, and muscular dystrophies. Somite's AI platform, AlphaStem, fuels a virtuous cycle: It enables new cell therapies, generating massive data that further improve the platform, empowering even faster therapy creation with broader applications. The company's pipeline includes the promising SMT-M01 program for Duchenne muscular dystrophy (DMD) and the SMT-B01 program for metabolic disorders. Incorporated in Oct. 2023,

Only accessible to MedStartr community members. Join now

Company Info

Founded
2023
Website
www.cellularintelligence.com/

Categories

AI / MLRegenerative MedicineTherapeuticsBiotech

Disease Areas

Technologies

Generative AIAI/Machine LearningCell TherapyTissue Engineering
Only accessible to MedStartr community members. Join now

What do you think of Somite AI?

A HUGE part of what early stage companies, and even late stage ones, need and get on MedStartr is honest feedback from actual patients, clinicians, hospital leaders and industry insiders. It is very easy to get tunnel vision as a founder. Please tell the team that runs this company what you think.

Innovation

Clinical Benefit

Feasibility

Scalability

Only accessible to MedStartr community members. Join now